Upadacitinib in Rheumatoid Arthritis-Associated Interstitial Lung Disease: Real-World Effectiveness and Safety from a National Multicenter Cohort (ACR Convergence 2026) - Sep 8, 2026 - Abstract #703; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Some JAK inhibitors (tofacitinib, baricitinib) may be useful, but evidence for upadacitinib (UPA) is limited...Patients had received a mean of 1.9 ± 0.8 conventional DMARDs and 1.6 ± 0.7 biologic DMARDs; many had been treated with anti-TNF (49%), tocilizumab (35%), abatacept (51%), and/or rituximab (26%)... In this national real-world cohort, UPA was associated with stable lung function, favorable HRCT and dyspnea, and meaningful improvement in joint disease. Importantly, many patients had long-standing RA-ILD and were refractory to multiple therapeutic targets-including several biologic agents-yet still achieved pulmonary and articular stability under UPA. These findings support UPA as a promising therapeutic option for RA-ILD in difficult-to-treat, highly pretreated patients."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Coronary Artery Disease • Fibrosis • Heart Failure • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lung Cancer • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Solid Tumor • Varicella Zoster
|
|
Pilar Ortiz1; Ana Serrano-Combarro2; Belén Atienza-Mateo2; César Antonio Egües Dubuc3; M. Pilar Bernabeu Gonzálvez4; Bryan-Josué Flores Robles5; Paula García-Escudero6; Rafael B. Melero-González7; Patricia López Viejo8; Juan Moreno Morales9; Andrea García Valle10; Ana Urruticoechea-Arana11; Jose Rosas12; Leticia del Olmo Perez13; Guillermo Gonzalez Mozo de Rosales14; Deseada Palma Sánchez15; Alicia García-Dorta16; Ignacio Braña Abascal17; Natalia Mena-Vázquez18; Juan Molina-Collada19; Sara García Pérez20; María José Pérez Galán21; Nuria Vegas Revenga22; Angel Garcia-Aparicio23; Juan Carlos Nieto González24; MARIA MARTIN25; Francisco Aramburu Muñoz26; Rafaela Ortega-Castro27; Gema Bonilla28; Sheila Izquierdo Cuervo29; Ricardo Blanco30
|